NovoCure director Timothy Scannell retires
NovoCure Ltd (NVCR) reported that director Timothy Scannell has retired from its Board of Directors, and his board seat was formally vacated in accordance with the company’s Articles of Association effective September 2, 2026.
Rhea-AI Filing Summary
NovoCure Ltd (NVCR) reported that director Timothy Scannell has retired from its Board of Directors, and his board seat was formally vacated in accordance with the company’s Articles of Association effective September 2, 2026.
The company stated that Mr. Scannell’s retirement after five years of service did not result from any disagreement with NovoCure or its management.
Positive
- None.
Negative
- None.
Insights
Analyzing...
8-K Event Classification
2 items: 5.02, 9.01
2 items
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Effective retirement date: September 2, 2026
Years of board service: 5 years
Form type: Form 8-K
3 metrics
Effective retirement date
September 2, 2026
Date Timothy Scannell’s board seat was formally vacated
Years of board service
5 years
Length of service by director Timothy Scannell before retirement
Form type
Form 8-K
Current report disclosing director retirement
Key Terms
Articles of Association, Emerging growth company, Inline XBRL
3 terms
Articles of Association regulatory
"his seat was formally vacated pursuant to the Company’s Articles of Association"
A company's articles of association are its written rulebook that sets how the business is run, how decisions are made, and what rights owners and directors have—covering voting, meetings, appointment and removal of directors, share classes and dividend policies. For investors, these rules matter because they determine how easily control can change, what protections minority owners have, and how corporate actions (like issuing new shares or changing leadership) are approved, much like a home’s bylaws shaping what residents can and cannot do.
Emerging growth company regulatory
"Emerging growth company o"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Inline XBRL technical
"Cover Page Interactive Data File (embedded within the Inline XBRL document)"
Inline XBRL is a file format for financial filings that embeds machine-readable data tags directly inside the human-readable report, so the same document can be read by people and parsed by software. For investors it makes extracting, comparing and verifying financial numbers faster and more reliable—like a grocery list where each item also has a barcode—reducing manual errors and speeding up analysis.
FAQ
What board change did NovoCure Ltd (NVCR) disclose on September 2, 2026?
NovoCure disclosed that director Timothy Scannell retired from the Board of Directors, and his seat was vacated pursuant to the company’s Articles of Association, effective September 2, 2026.
Did Timothy Scannell’s retirement from NovoCure’s (NVCR) board involve any disagreement?
No. NovoCure stated that Mr. Scannell’s retirement from the board after five years of service did not result from any disagreement with the company or its management.
What is the effective date of the board change reported by NovoCure (NVCR)?
The effective date of the board change is September 2, 2026, when director Timothy Scannell’s retirement took effect and his board seat was formally vacated.
Who signed NovoCure’s (NVCR) report about the director’s retirement?
The report was signed on behalf of NovoCure by Christoph Brackmann, who is identified as the company’s Chief Financial Officer, dated September 9, 2026.
Which security of NovoCure Ltd (NVCR) is registered on a national exchange?
NovoCure lists its Ordinary Shares, no par value, under the trading symbol NVCR on The Nasdaq Stock Market LLC, as stated in the report.
AI-generated analysis. How Rhea-AI works. Not financial advice.
